Patents by Inventor Tim Beaumont

Tim Beaumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20230242667
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 3, 2023
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 11629200
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 18, 2023
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20210277094
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: June 18, 2020
    Publication date: September 9, 2021
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20200325213
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20200317754
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 10730931
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 4, 2020
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20200239593
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 30, 2020
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • RSV-specific binding molecule
    Patent number: 10723786
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 28, 2020
    Assignee: MedImmune, Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20200149007
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: September 19, 2019
    Publication date: May 14, 2020
    Inventors: PAULA MARIA WILHELMINA VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen Spits, Tim Beaumont
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • Hepatitis C virus specific antibody
    Patent number: 10435463
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: October 8, 2019
    Assignee: ACADEMISCH MEDISCH CENTRUM
    Inventors: Tim Beaumont, Sabrina Julia Louisa Merat, Cornelia Johanna Schinkel, Richard Molenkamp
  • Means and methods for producing high affinity antibodies
    Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 10273454
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 30, 2019
    Assignee: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20190040120
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 7, 2019
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20180327484
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20180292391
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 11, 2018
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • RSV-specific binding molecules and means for producing them
    Patent number: 10059757
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecule
    Patent number: 10035843
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 31, 2018
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV G protein specific antibodies
    Patent number: 10017562
    Abstract: The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 10, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Means and methods for producing high affinity antibodies
    Patent number: 9969795
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: May 15, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner